Laurion Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$266K Buy
1,441
+286
+25% +$62.2K ﹤0.01% 376
2026
Q2
$283K Buy
+1,155
New +$250K 0.01% 365
2019
Q2
– Sell
-219,000
Closed -$3.12M – 892
2019
Q1
$3.12M Buy
+219,000
New +$2.03M 0.04% 267

Other funds holding AXSM

Laurion Capital Management's AXSM Position: Q3 2026 in Review

Laurion Capital Management increased its Axsome Therapeutics (AXSM) stake by 25% in Q3 2026, buying an estimated $62.2K and bringing the position to 1,441 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #376.

Laurion Capital Management first reported a position in AXSM in Q1 2019 and has held it in 3 quarters since. The position peaked at $3.12M in Q1 2019. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Laurion Capital Management held 1,441 shares of Axsome Therapeutics worth $266K as of Q3 2026.
  • Laurion Capital Management bought 286 Axsome Therapeutics shares in Q3 2026, an estimated $62.2K.
  • Axsome Therapeutics made up ﹤0.01% of Laurion Capital Management's portfolio in Q3 2026, its #376 holding.
  • Laurion Capital Management first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Laurion Capital Management's Axsome Therapeutics position peaked at $3.12M in Q1 2019.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Laurion Capital Management's 13F filing for Q3 2026, filed 30 Oct 2026.